Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) were evaluated as predictors of response to IO, bu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	HNSCC TMB immunotherapy immune checkpoint inhibitors PD-L1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a7f390719f544458b4a07425f2995346
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7f390719f544458b4a07425f2995346
record_format	dspace
spelling	oai:doaj.org-article:a7f390719f544458b4a07425f29953462021-11-25T17:03:24ZRelationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma10.3390/cancers132257332072-6694https://doaj.org/article/a7f390719f544458b4a07425f29953462021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5733https://doaj.org/toc/2072-6694Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) were evaluated as predictors of response to IO, but the results are inconsistent and with a lack of standardization of their methods. In this retrospective study, TMB and PD-L1 were measured by commercially available methodologies and were correlated to demographics, outcome, and response to PD-1 inhibitors. No correlation was found between TMB and PD-L1 levels. High TMB was associated with smoking and laryngeal primaries. PD-L1 was significantly higher in African Americans, patients with earlier stage tumors, nonsmokers, and nonethanol drinkers. Patients with high TMB fared better in univariate and multivariate survival analysis. No correlation was found between PD-L1 expression and prognosis. There was a statistically significant association between PFS and response to IO and TMB. There was no association between response to ICI and PD-L1 in this study, possibly affected by variations in the reporting method. Further studies are needed to characterize the biomarkers for IO in HNSCC, and this study supports further research into the advancement of TMB in prospective studies.Kimberly M. BurcherJeffrey W. LantzElena GavrilaArianne AbreuJack T. BurcherAndrew T. FaucheuxAmy XieClayton JacksonAlexander H. SongRyan T. HughesThomas LycanPaul M. BunchCristina M. FurduiUmit TopalogluRalph B. D’AgostinoWei ZhangMercedes PorosnicuMDPI AGarticleHNSCCTMBimmunotherapyimmune checkpoint inhibitorsPD-L1Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5733, p 5733 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HNSCC TMB immunotherapy immune checkpoint inhibitors PD-L1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	HNSCC TMB immunotherapy immune checkpoint inhibitors PD-L1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kimberly M. Burcher Jeffrey W. Lantz Elena Gavrila Arianne Abreu Jack T. Burcher Andrew T. Faucheux Amy Xie Clayton Jackson Alexander H. Song Ryan T. Hughes Thomas Lycan Paul M. Bunch Cristina M. Furdui Umit Topaloglu Ralph B. D’Agostino Wei Zhang Mercedes Porosnicu Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
description	Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) were evaluated as predictors of response to IO, but the results are inconsistent and with a lack of standardization of their methods. In this retrospective study, TMB and PD-L1 were measured by commercially available methodologies and were correlated to demographics, outcome, and response to PD-1 inhibitors. No correlation was found between TMB and PD-L1 levels. High TMB was associated with smoking and laryngeal primaries. PD-L1 was significantly higher in African Americans, patients with earlier stage tumors, nonsmokers, and nonethanol drinkers. Patients with high TMB fared better in univariate and multivariate survival analysis. No correlation was found between PD-L1 expression and prognosis. There was a statistically significant association between PFS and response to IO and TMB. There was no association between response to ICI and PD-L1 in this study, possibly affected by variations in the reporting method. Further studies are needed to characterize the biomarkers for IO in HNSCC, and this study supports further research into the advancement of TMB in prospective studies.
format	article
author	Kimberly M. Burcher Jeffrey W. Lantz Elena Gavrila Arianne Abreu Jack T. Burcher Andrew T. Faucheux Amy Xie Clayton Jackson Alexander H. Song Ryan T. Hughes Thomas Lycan Paul M. Bunch Cristina M. Furdui Umit Topaloglu Ralph B. D’Agostino Wei Zhang Mercedes Porosnicu
author_facet	Kimberly M. Burcher Jeffrey W. Lantz Elena Gavrila Arianne Abreu Jack T. Burcher Andrew T. Faucheux Amy Xie Clayton Jackson Alexander H. Song Ryan T. Hughes Thomas Lycan Paul M. Bunch Cristina M. Furdui Umit Topaloglu Ralph B. D’Agostino Wei Zhang Mercedes Porosnicu
author_sort	Kimberly M. Burcher
title	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
title_short	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
title_full	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
title_fullStr	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
title_full_unstemmed	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
title_sort	relationship between tumor mutational burden, pd-l1, patient characteristics, and response to immune checkpoint inhibitors in head and neck squamous cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a7f390719f544458b4a07425f2995346
work_keys_str_mv	AT kimberlymburcher relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT jeffreywlantz relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT elenagavrila relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT arianneabreu relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT jacktburcher relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT andrewtfaucheux relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT amyxie relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT claytonjackson relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT alexanderhsong relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT ryanthughes relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT thomaslycan relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT paulmbunch relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT cristinamfurdui relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT umittopaloglu relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT ralphbdagostino relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT weizhang relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma AT mercedesporosnicu relationshipbetweentumormutationalburdenpdl1patientcharacteristicsandresponsetoimmunecheckpointinhibitorsinheadandnecksquamouscellcarcinoma
_version_	1718412794821345280

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

Ejemplares similares